Using the virtual reality (VR) platform, doctors can show patients, in an immersive, highly detailed way, what will happen to their bodies if they take their medication, stop smoking, and eat better — and what will happen if they don't.
Recent decades have seen an "explosive evolution" of techniques to restore blood flow to areas of the brain endangered by stroke or clogged arteries, according to a report by Loyola Medicine neurologists and neurosurgeons.
Patient monitoring system developer Leaf Healthcare today released results from a study exploring the ability of its Leaf wearable patient sensor to prevent pressure injuries on acutely ill adults, touting that patients were 73% less likely to develop such injuries when monitored with the device.
Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. The drug has been cleared to treat a range of indications spanning carcinoma of the colon or rectum, breast cancer; nonsquamous non-small cell lung cancer, renal cell cancer; platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer. The companies noted that the approval came after trial data showed a high degree of similarity between Mvasi (biosimilar bevacizumab) and its reference drug, “with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products”. Mvasi is the first product borne out of an alliance between Amgen and Allergan to bag marketing authorisation from the European Commission, “highlighting the success of our joint commitment to developing cancer biosimilars,” noted David Nicholson, chief research and development officer at ...
Tweeting to the top, GlaxoSmithKline and Pfizer tied for the No. 1 spot in the inaugural ranking of global pharma influencers by Owen Health. The U.K.-based healthcare marketing agency evaluated 22 pharma companies on authority, reach, activity, engagement and influence to rate the most and least adept when it comes to Twitter.
Healthcare organizations should use risk management processes to ensure the security of health information and protect against the vulnerabilities stemming from the Spectre and Meltdown threats.
Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.
Earning a little extra toward workout products and fitness classes could be as easy as tracking the steps you take outside. London-based Sweatcoin, a company which “pays” users a digital currency based on their daily steps, has just landed $5.7 million in a funding round led by Goodwater Capital with participation from Seedcamp, Greylock Partners, Rubylight, SmartHub, and several angel investors.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.